INTRODUCTION
Endometrial cancer (EC) is the commonest gynecological malignancy in the Western world, and affects approximately 150,000 women each year in Europe and the US combined (1) . ECs have traditionally been classified into endometrioid (EEC) and non-endometrioid (NEEC) tumors according to clinical and histopathological criteria. However, recent work has shown that this dualistic model can be improved upon by a molecular classification into subgroups that more accurately reflect underlying tumor biology and clinical outcome (2, 3) .
One interesting subgroup is the 7-12% of ECs with somatic mutation in the proofreading exonuclease domain of the DNA replicase POLE (2, (4) (5) (6) . Polymerase proofreading is essential for ensuring fidelity of DNA replication (7) , and in keeping with its dysfunction, POLE proofreading-mutant cancers have a frequency of base substitution mutation among the highest in human cancer (2, 8, 9) . POLE-mutant ECs display other distinctive features, including a characteristic mutation signature, with a preponderance of C>A transversions and bias for particular amino acid substitutions, and strong associations with endometrioid histology, high grade, and microsatellite stability (MSS) (2, (4) (5) (6) 10) .
We and others have recently shown that, despite the association with high grade, POLE-mutant ECs have an excellent prognosis (5, 6, 11) . However, the reasons for this were unclear.
Although the ability of the immune system to suppress malignant disease has long been recognized (12) , the last few years have seen a remarkable increase in our understanding of the complex and dynamic interplay between cancers and the host immune response. For example, preclinical and translational studies have confirmed that tumor missense mutations can lead to presentation of antigenic neo-epitopes by MHC class I molecules, resulting in activation of T cell-mediated cytotoxicity (13) (14) (15) (16) . Consequently, mutations that cause strongly antigenic epitopes are likely to undergo negative selection in developing tumors (13, 14) . Cancers also demonstrate multiple alternative mechanisms of immune escape, including downregulation of HLA class I expression, and upregulation of immunosuppressive molecules including PD1/PD-L1, TIM3, LAG3 and TIGIT in a phenomenon referred to as adaptive immune resistance (17, 18) . Despite this, it is clear that in many cancers the immune system retains a degree of control over tumor growth -illustrated by the association between increased density of tumor infiltrating lymphocytes (TILs), particularly CD8 + cytotoxic T cells, and favorable outcome in multiple cancer types, including EC (19) (20) (21) (22) . Interestingly, a recent study has shown that CD8 + cell infiltration correlates strongly with the number of predicted antigenic mutations in tumors (23) , suggesting that the immunogenicity of cancers is determined at least partly by their mutational burden (24) . These data are consistent with the observations that hypermutated microsatellite unstable (MSI) endometrial and colorectal cancers typically display greater TIL density than other tumors (25, 26) .
Chapter 7
During our previous studies (4) (5) (6) , we noted that POLE-mutant ECs frequently displayed strikingly high TIL density, often accompanied by a Crohn's-like reaction. Similar observations have recently been reported following pathological review of POLE-mutant TCGA ECs (27) . We hypothesized that this may represent infiltration by cytotoxic T lymphocytes, which could in turn contribute to the favorable prognosis of these tumors. We also speculated that this might relate to an increase in antigenic neo-epitopes in POLE-mutant ECs secondary to ultramutation. We tested this using a molecularly defined cohort of ECs, including 47 POLE-mutant tumors, and the recently published TCGA series (2) .
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MATERIALS AND METHODS

Patients and tumors
Tumors were selected from the PORTEC-1 and PORTEC-2 studies (n=57) (28, 29) and EC series from the Leiden University Medical Centre (LUMC) (n=67) and the University Medical Centre Groningen (UMCG) (n=26), to provide similar numbers of low (grade 1/2) and high grade (grade 3) tumors of the common molecular subtypes: POLE wild-type, microsatellite stable (MSS); POLE wild-type, microsatellite unstable (MSI); and POLE (proofreading) mutant ( Table 1 ). All cases were of endometrioid histology (EEC), and all POLE-mutant tumors were MSS. Of 373 cases reported in the TCGA series, 245 had paired whole exome and RNAseq data and were informative for this analysis (2) . Of these 197 were EECs, four mixed EEC/NEECs, and 44 serous (NEEC) cancers. Ethical approval for tumor molecular analysis was granted at LUMC, UMCG and by Oxfordshire Research Ethics Committee B (Approval No. 05\Q1605\66).
POLE mutation and microsatellite instability status
DNA was extracted from FFPE blocks and sequencing of POLE hotspot exons 9 and 13 (which contain around 90% of pathogenic proofreading mutations) was performed in tumors from the PORTEC, LUMC and UMCG series as previously reported (4, 5) . All mutations were confirmed in at least duplicate PCR reactions. Details of whole exome sequencing performed by the TCGA have been previously reported (2) . Pathogenic POLE proofreading mutations were defined as somatic variants within the exonuclease domain associated with ultramutation and a frequency of C>A transversions of ≥20%(10).
MSI status was determined in the PORTEC, LUMC and UMCG cases by five-marker panel of microsatellites as reported previously (30) , with exception of four cases in which this failed, where status was determined by MLH1, MSH2, MSH6 and PMS2 immunohistochemistry (6) . Determination of MSI in the TCGA series was by seven-marker panel, with MSI-H defined as alteration at ≥3 markers (2) .
Classification of POLE mutant TCGA ECs was also informed by results of recent analysis of mononucleotide repeats in 48 genes (10) . In our analysis, only MSI-H cases were classified as MSI -we excluded one TCGA case for which MSI status could not be determined. The single tumor that displayed both POLE proofreading mutation and MSI by these criteria was assigned to the POLE mutant group on the basis of its characteristic mutation signature, in accordance with a recent report (10) .
Histological assessment
Tumors were evaluated for the presence/absence of TILs and for Crohn's like reaction by a gynecologic pathologist (TB) blinded to other clinicopathological data. Philips), and analysis.
CD8 + , CD3 + , FOXP3 + and TIA-1 + cell numbers were quantified in intraepithelial and intrastromal regions in the center of the tumor (CT) and the invasive margin (IM) as previously reported (19, 22) . and HC10 staining was quantified as previously described (31) . In each case, scoring was performed independently by two observers, blinded to other clinicopathological data.
Immunofluorescence
Following de-paraffinization, antigen retrieval and blocking of peroxidase activity, whole slides were stained overnight at 4°C with primary antibody against TIA-1 (1:50, ab2712, Abcam). Sections were subsequently incubated with anti-mouse Envision+ reagent (K4000, DAKO) for 30 minutes and HRP visualized using cyanine 5 tyramide signal amplification (TSA) according to the manufacturer's instructions (PerkinElmer). Next, whole slides were stained overnight with primary antibody against CD8 (1:25, clone C8/144B, DAKO) and a biotinylated antibody against fibronectin (1:50, ab6584, Abcam). Slides were incubated with GaM-AF555 (1:150 Life Technologies) and streptavidin-dy-light488 (1:150, Thermo Scientific), counterstained with DAPI (Life Technologies) and mounted in prolong gold mounting medium (Life Technologies). Immunofluorescent slides were scanned using a TissueFaxs imaging system (TissueGnostics, Austria). Processed channels were merged using Adobe Photoshop CS5 (Adobe).
Leukocyte methylation scores
Leukocyte methylation scores (syn1809223) (32, 33) were downloaded from Synapse (https://www. synapse.org/) and annotated according to MSI and POLE status.
TCGA RNAseq data
Details of the TCGA RNAseq analysis have been previously reported (2) . RSEM normalized (34) (18) .
Prediction of antigenic neo-epitopes
We created an algorithm to estimate the immunogenicity of individual tumors taking into account the following considerations: i) to generate a functional neo-epitope a missense mutation must be expressed; ii) most functional neo-epitopes identified to date are predicted to bind MHC class I molecules (IC 50 < 500nM) by NetMHCPan (23, 37, 38) ; iii) the likelihood that a neo-epitope is antigenic is reduced if the corresponding wild-type peptide also binds the MHC with similar affinity as T cells to the epitope may be centrally deleted or tolerized (39) . Our strategy was similar to others reported recently (15, 23, 38, 40) . For each tumor we calculated all possible 9mers for every missense mutation in expressed genes (defined as non-zero reads from RNAseq) and calculated the binding affinity of the mutant and corresponding wild-type peptide for HLA-A*02:01 (as a single model example HLA allele) using NetMHCPan 2.8 (37) . In the event that several peptides had an IC 50 <500nM, the strongest binder was used for analysis. We defined antigenic mutations as neo-epitopes predicted to bind MHC molecules (IC 50 < 500nM) for which the corresponding wild-type peptide was not predicted to bind MHC (IC 50 > 500nM).
Statistical analysis
We used the non-parametric Mann-Whitney test for all comparisons of continuous data and Spearman's rho to analyze correlation between variables. Categorical variables were compared using
Fisher's exact test. All statistical tests were two-sided, with a P value of <0.05 taken to indicate significance. Except where indicated, statistical tests were unadjusted. Statistical analyses were performed using STATA (Texas), and Prism 6.0 (GraphPad, LaJolla).
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RESULTS
POLE proofreading-mutant ECs show increased lymphocytic infiltrate
Preliminary analysis of H&E-stained sections suggested that POLE proofreading-mutant ECs frequently displayed a prominent lymphocytic infiltrate and Crohn's-like lymphocytic reaction ( Figure   1A ,B Fisher's exact test), and MSI (10/49; P=0.009) subtypes ( Figure 1C ). Crohn's-like reaction was also significantly more common in POLE-mutant than other tumors (P<0.001 both comparisons; Figure 1D ).
Increased density of intratumoral CD8 + lymphocytes in POLE-mutant ECs
Mindful of the relationship between cytotoxic T cell infiltrate and favorable cancer outcome (19) (20) (21) (22) , and the excellent prognosis of POLE-mutant ECs(5,6,11), we next examined whether POLE-mutants showed evidence of increased T cell infiltrate in our EC cohort. While as anticipated (25) Figure 2B ). Furthermore, the proportion of tumors with numbers of CD8 + cells exceeding the median in all four regions was substantially higher in POLE-mutant (60.0%) than MSI (31.3%, P=0.007, Fisher's exact test) and MSS tumors (7.2%, P<0.0001). Staining for CD3 and the cytolytic marker TIA-1 in a subset of cases confirmed increased T cell density in POLE-mutant tumors ( Figure 3A ,B) and suggested that the infiltrate contained lymphocytes capable of cytotoxic activity ( Figure 4A,B ). Co-immunofluorescence confirmed co-expression of TIA-1 in the CD8 + lymphocytes comprising the POLE-mutant tumor infiltrate ( Figure 5A -F), further supporting the conclusion that these cells were capable of mediating an anti-tumor effect.
Interestingly, in light of the correlation previously reported between B and T cell subsets at the IM(41), we found that dense CD20 stromal infiltrate in this region was more common in POLE-mutants ( Figure 6A ), while a tendency to increased numbers of FOXP3 + cells in both MSI and POLE-mutant tumors ( Figure 6B ) was also notable, given that this has been associated with favorable cancer prognosis in some studies (41) . 
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Cytotoxic T cell infiltration and activation in POLE mutant ECs in TCGA series
We sought to confirm our results using the TCGA EC series (2) , in which the improved clinical outcome of POLE-mutant tumors was first suggested ( Figure 7A ). Of 244 informative tumors in this study, 157
were MSS, 69 MSI and 18 POLE-proofreading-mutant (the single tumor with both POLE proofreading mutation and MSI was categorized as POLE-mutant according to its mutation spectrum, in keeping with a recent report (10)). 43 of the MSS tumors were NEECs, while all MSI and POLE-mutant ECs cases were EECs (Table 1) .
We first examined leucocyte methylation scores, which estimate the proportion of heterogeneous tumor sample that consists of leucocytes (32, 33) . After confirming that scores correlated strongly with CD8A expression (ρ=0.65, P<0.0001), we noted that, following exclusion of MSI and POLE-mutant tumors, both leucocyte methylation scores and CD8A expression did not differ between EECs Figure 7B ), concordant with our previous results. Given the biological differences between NEECs and EECs, we formally confirmed that these results were essentially unaltered following exclusion of the former from the MSS group (median 14.7%, P=0.008 vs POLE-mutant ECs).
We proceeded to explore whether infiltration of Upregulation of most of these genes in tumors has been shown to predict good prognosis (19, 41) .
POLE-mutants also demonstrated striking upregulation of the T follicular helper genes CXCL13 (7.0-fold, P=0.0001) and CXCR5 (3.9-fold, P=0.0004), which have recently been shown to strongly predict favorable outcome in colorectal cancer (41) . Notably, despite limited numbers, in several cases expression of cytotoxic markers and cytokines exemplifying effector status in POLE mutants significantly exceeded that in MSI tumors (e.g. PRF, P=0.02; GZMH P=0.04; CXCL9/10 both P=0.03) (Figures 7 and 8) . Collectively, these data not only corroborated our previous finding that POLE mutant tumors had greater T lymphocyte infiltration than other ECs, but also strengthened the conclusion that these lymphocytes were capable of exerting anti-tumor activity.
Mechanisms of immune escape in POLE-mutant ECs
POLE-mutant cancers have significantly better prognosis than other ECs (5, 6, 11) , as evidenced by the absence of recurrences in the TCGA series (2) . However, the presentation of all patients in this study with clinically detectable tumors, in some cases with lymphatic spread, indicates that any 139 Immunity of POLE-mutant endometrial cancer immune response was, at best, only partially successful in suppressing POLE-mutant EC growth. We therefore explored potential mechanisms of immune escape in these tumors.
We first considered the possibility that POLE-mutant ECs may escape from immune surveillance by loss or inactivation of components required for antigen presentation. While 31.8% of POLE mutant ECs in our study set of 150 ECs showed loss of HLA class I protein expression by IHC, this was not significantly different to that observed in MSI (28.6%, P=0.82, Fisher's exact test) or MSS (20.0%, P=0.24) tumors and was not reflected in increased CD8 + cell numbers. Similarly, although we found a tendency to over-representation of POLE mutants among TCGA ECs with HLA class I gene expression in the lowest quartile, this was also not significantly different from other molecular subtypes (P=0.07 vs MSS).
Interestingly, while mutations in MHC pathway components were common in POLE-mutant tumors in the TCGA series, most were of unlikely pathogenicity, with exception of two tumors with potentially functional variants. The first, a beta 2-microglobulin R117* mutation also detected in a POLE-mutant CRC(9), had a variant allele fraction of 0.59 and is likely to affect stability of the MHC complex by disruption of the interaction with the HLA heavy chain (42) . The second, an HLA-B S112R substitution with variant allele fraction 0.71, lies near the F pocket essential for peptide display, and is predicted to be deleterious by both Mutation Assessor and SIFT (Table 2 ). However, the effect of each variant on antigen presentation is, at present, uncertain.
We proceeded to examine whether the cytotoxic T cell response in POLE-mutant ECs may be attenuated by upregulation of immunosuppressive mediators -a phenomenon termed adaptive immune resistance (17) . We found that the T cell exhaustion markers LAG3, TIM-3 and TIGIT, and the T cell inhibitors PD1 and CTLA4 were strongly correlated with CD8A expression across all ECs of all molecular subtypes (ρ=0.65 to 0.87; P<0.0001, all cases), though the correlation with PD-L1 was more modest (ρ=0.34, P<0.0001) ( Figure 9A ). Interestingly, while expression of these markers in MSI compared to MSS ECs was either unchanged/minimally altered (TIM-3, CTLA4, PD-L1) or moderately increased (LAG3 1.9 fold, P<0.002; TIGIT 2.2 fold, P<0.0001), in POLE mutants all were significantly, and substantially upregulated (e.g. LAG3 2.9 fold, P<0.0001 vs. MSS, P<0.02 vs. MSI; TIGIT 3.6 fold, P<0.0001 vs. MSS, P<0.15 vs. MSI) ( Figures 7D and 9B) , consistent with prolonged antigen stimulation. However, as noted above, the overall increase in expression of cytotoxic effector markers suggested that this upregulation was insufficient to fully suppress the T cell response in POLE mutants. (P<0.001, all cases) .
A, Correlation between CD8A expression and T cell exhaustion markers
B, T cell exhaustion markers according to EC molecular subtype. Box and whiskers signify IQR ± 1.5 x IQR, mean and median as previously. Statistical comparison between groups was made by unadjusted
Mann-Whitney test, *, **, and *** correspond to P<0.05, P<0.01, and P<0.001 respectively.
POLE proofreading-mutant ECs are likely to display increased numbers of antigenic neopeptides
We hypothesized that the T cell response in POLE-mutant ECs might be due to an excess of antigenic neo-epitopes as a consequence of ultramutation. To quantify this, we analyzed the TCGA EC series using a methodology similar to several recent studies (23, 40) . Our algorithm was based on three assumptions -first, that a mutation must be in an expressed gene to exert an effect, second, for a neopeptide to act as an antigen it must bind MHC class I molecules (IC 50 <500nM), and third, that neopeptides for which the corresponding wild-type peptide also binds MHC molecules are less likely to be immunogenic due to central deletion or tolerization (39) .
Applying these criteria, we found that 5.9% (7880/134,473) of the total number of missense mutations in TCGA ECs were predicted to be potentially antigenic. Of these, 73% (5767) occurred in POLE-mutant tumors, reflected in a significantly higher number of antigenic mutations per cancer compared to both MSI and MSS subtypes (median 365.5 vs 16 vs 2 respectively, P<0.0001 all comparisons, Mann-Whitney test) ( Figure 10A ), though this is likely to underestimate the number of antigenic mutations in MSI tumors as frameshift mutations were not included in our analysis.
A substantial majority of antigenic mutations were in tumors with greater than median CD8A expression in both the whole series (78.4%), and the POLE-mutant subgroup (83.9%), though the strength of correlation between the two variables was modest, possibly as a result of immune escape mechanisms ( Figure 10B ).
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DISCUSSION
By complementary analysis of two independent series totaling nearly four hundred patients, and including over sixty POLE-proofreading mutant tumors, we have shown that POLE-mutant ECs are characterized by a striking CD8 + lymphocytic infiltrate, a gene signature of T cell infiltration, and marked upregulation of cytotoxic T cell effector markers. Furthermore, we show that, as a consequence of their remarkable mutation burden, POLE proofreading-mutant cancers are predicted to display substantially more antigenic peptides than other tumors, providing a possible explanation for our findings. While our data demonstrate correlation rather than causation, the strong association between cytotoxic lymphocyte infiltration and favorable outcome in multiple cancers (19) (20) (21) (22) 41) leads us to speculate that an enhanced T cell anti-tumor response may contribute to the excellent prognosis of POLE-mutant ECs.
During the last few years, a combination of next generation sequencing technology, improved in silico peptide-MHC binding prediction (37) , and the clinical application of immune checkpoint inhibitors (43) (44) (45) have helped facilitate remarkable insights into the mechanisms of tumor immunoediting and immune escape. The intriguing observation that clinical benefit from CTLA4, PD1 and PD-L1 inhibition is greater in melanoma and cigarette smoking-associated lung cancer than most other malignancies can now be interpreted in light of the understanding that in these highly mutated tumors, adaptive immune resistance is a key enabler of disease progression (17) , and its inhibition can restore the ability of T cells to respond to antigenic peptides presented by these cancers (43) .
In keeping with this, in melanoma response to checkpoint inhibitors has very recently been shown to correlate both with the number of predicted antigenic tumor mutations (40) , and with the degree of cytotoxic T lymphocyte tumor infiltration prior to treatment (46) . In light of these data, the association between the number of predicted antigenic peptides and T cell response in POLE mutant ECs in our study is noteworthy, as is the marked increase in T cell exhaustion markers, as these have recently been shown to identify tumor neo-antigen-specific CD8 + cells in cancer patients (47, 48) .
Despite upregulation of these immunosuppressors in POLE-mutant ECs, we also found substantial increases in cytotoxic differentiation markers and effectors suggesting that the degree of adaptive immune resistance in these cancers may be insufficient to fully suppress CD8 + T cell cytotoxicity (49) .
Collectively, our data suggest a complex interaction between the antigenic landscape of POLE-mutant ECs and the immune response. In this regard, molecular analysis of recurrences from the few patients with POLE-mutant ECs who do experience relapse may provide insights into mechanisms of immune escape. Lastly, these patients may be good candidates for immune checkpoint inhibitor therapy, as might those patients with POLE proofreading-mutant tumors of other histologies, for which outcomes are more uncertain.
Interestingly, while as anticipated we observed moderately increased T cell infiltration in MSI tumors (25) , this was not associated with the marked increase in cytotoxic effector markers seen 145 Immunity of POLE-mutant endometrial cancer in POLE mutants. While some studies have reported improved prognosis of MSI ECs, this is inconsistent (50) , in contrast to the clear association of MSI with favorable outcome in early colorectal cancer (26) . Comparison of the immune response between MSI tumors of both types may provide insights into this discordance.
Our study has limitations. Due to differing sample preservation (FFPE vs fresh frozen) we were unable to validate either the IHC or RNAseq analysis between series, although the results from both analyses were highly concordant. Furthermore, the retrospective nature of our study meant that we were unable to investigate the repertoire and antigen response of T cells in patients with POLE-mutant cancers. This and other functional analyses will require prospective investigation.
In summary, we have demonstrated that ultramutated POLE proofreading-mutant ECs are characterized by a robust intratumoral T cell response, which correlates with, and may be caused by an enrichment of antigenic neo-peptides. Our study provides a plausible mechanism for the excellent prognosis of these cancers, and further evidence of the link between somatic mutation and immunoediting in cancers. 
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